GPM Investments Campaign Raises More Than $244K for ALS, Other Neuromuscular Diseases
GPM Investments raised $244,263 for patients with amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders in its eighth holiday…
Articles by José Lopes, PhD
New Diagnostic Index Enables Earlier ALS Diagnosis, Study Reports
A new diagnostic score accounting for age at disease onset and motor neuron dysfunction in the brain is able to…
MAP4K4 Enzyme a Potential Therapeutic Target in ALS, Study Suggests
Suppressing an enzyme known as MAP4K4 extended the survival of motor neurons collected from mice and patients with amyotrophic…
New Rat Model Enables Better Study of Swallowing Issues in ALS, Researchers Say
A new, more targeted rat model of swallowing problems may lead to better understanding of ways to preserve and even…
Anticonvulsant Potiga Lowers Motor Neuron Excitability in ALS Patients, Phase 2 Trial Shows
Treatment with the anticonvulsant Potiga (ezogabine) lessened abnormal motor neuron excitability, or responsiveness, in patients with amyotrophic lateral…
Device That Reproduces Food Flavors May Benefit ALS Patients, Study Reports
Amyotrophic lateral sclerosis (ALS) patients with impaired swallowing show loss of taste perception, according to a new study. This…
Brain’s Waste Removal System Could Improve Delivery of Therapies to Brain, Study Suggests
The brain’s waste clearance pathway, known as the glymphatic system, could enable more efficient delivery of therapeutics into the brain…
Gene Therapy That Lowered SOD1 Protein in Primates Could Be Effective in ALS, Study Suggests
A gene therapy effectively and safely lowered the production of a key amyotrophic lateral sclerosis (ALS) protein called superoxide…
Multiple Rare Mutations in Genes Linked to ALS Can Lead to Earlier Disease Onset, Study Reports
People with multiple rare mutations in genes known to cause amyotrophic lateral sclerosis (ALS) are significantly more likely to…
Inosine Treatment Found Safe with Potential Benefits for ALS Patients in Pilot Trial
Treatment with a compound called inosine over 12 weeks increased the levels of the antioxidant urate, a neuroprotective agent, in…